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Increased tissue stiffness is a hallmark of cancer and promotes tumor 
progression. It is hypothesized that decreased tumorous stress may aid or 
sensitize chemotherapies. To overcome extracellular matrix (ECM) stiffening 
and fulfill sensitized chemotherapy in one nanosystem, a reactive  
oxygen species-activatable nanoenzyme (SP-NE) based on a dendritic poly-
glycerol scaffold, integrating collagenase and paclitaxel (PTX) prodrug, is 
constructed. The dense and tough ECM is highly remitted by SP-NE in the 
tumor microenvironment (TME) mimicking gelatin hydrogel models, which 
causes cell shrinkage, disorders cytoskeletal constructions, and subsequently 
enhances chemotherapeutic efficacy. ECM softening via SP-NE downregu-
lates mechanotransduction signaling pathways of integrin-focal adhesion 
kinase (FAK)-Ras homolog family member A (RhoA) implicated in cytoskel-
etal assembly, and integrin-FAK-phosphorylated extracellular signal regulated 
kinase (pERK 1/2) mediating mitosis. Notably, this programmed nanosystem 
in human breast MCF-7 tumor-bearing mice models displays a significant 
relief of ECM stress from 4300 to 1200 Pa and results in 87.1% suppression 
of tumor growth at a low PTX dosage of 3 mg kg−1. The attenuated expres-
sion of the key players RhoA and pERK 1/2 involved in cellular mechano-
sensing is further verified in vivo. This study thus provides a new and 
potential nanoplatform to selectively decrease TME stiffness for enhanced 
chemotherapy.
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1. Introduction
Nanomedicines for anti-cancer applica-
tions have been perplexed by compro-
mised therapeutic benefits in clinic for a 
long time.[1–4] It is increasingly recognized 
that one of the major causes for the failure 
of nanomedicines in clinic is the compli-
cated and unique biology of tumor micro-
environment (TME),[5,6] which consists 
of tumorous extracellular matrix (ECM), 
tumor associated fibroblasts, growth fac-
tors, vasculature, as well as immune 
cells.[7–9]
As one of the pivotal features of tumor 
micromilieu, the mechanical stiffness in 
tumor contexts is typically higher than 
that in healthy tissues,[10,11] which is uti-
lized as the basis for manual palpation 
and mammographic density screening in 
clinical diagnosis of breast cancer.[12] The 
increased breast tissue rigidity is always 
linked with an elevated risk of high malig-
nancy, as well as poor prognosis in cancer 
patients.[13,14] On a cellular level, matrix 
stiffness as an external input, regulates 
integrin clustering, focal adhesion for-
mation, cytoskeletal meshwork and the 
morphogenesis via activating a cascade of mechanical feed-
back loops, guiding cell behavior and even determining cell 
fate.[15,16] The signaling cascade includes Ras homolog (Rho) 
family guanosine triphosphatases such as RhoA, which mod-
ulates actin assembly and induces cell survival. Additionally, 
mitogen-activated protein kinase-extracellular signal-regulated 
kinase (MAPK-ERK) pathway, which is involved in mitosis 
and cell proliferation, is also initiated when receiving extrinsic 
mechanical cues.[17] Of late, both of RhoA and ERK have been 
reported to play a role in sensitizing cancer cells to chemo-
therapy.[18,19] Therefore, it is speculated that decreasing the 
solid stress in TME may favor or sensitize chemotherapy via 
altering the cellular priming state.
Recently, a multitude of efforts have been devoted to nor-
malization or modulation of TME for enhanced tumor penetra-
tion,[20–22] promoted nanoparticle accessibility to cancer cells,[23] 
improved drug delivery within tumors,[24] as well as relief 
of tumor hypoxic and immunosuppressive conditions.[25–27] 
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However, mechanical remodeling of tumorous ECM for 
enhanced cancer chemotherapeutic response in one nano-
system and the potential underlying mechanism remains 
elusive. The tumorous ECM stiffening is attributed to sev-
eral factors including overproduction of ECM components 
(collagens, fibronectins, proteoglycans), and elevated expres-
sion of lysyl oxidase, which mediates covalently intra- and inter-
molecular crosslinking of collagens.[28,29] The protease enzyme 
collagenase, which can effectively digest collagen, was reported 
to efficiently modify the dense and tough structure of ECM for 
promoted tumor penetration of nanoparticles or antibodies, 
resulting in enhanced chemo-, photodynamic, and antibody 
therapies.[30–32] Different from the above, in our mechanical 
remodeling of TME to sensitize chemotherapeutics strategy, the 
aim of collagenase digestion of ECM is to research the effect of 
different quantified tumor mechanical modulus on mechanical 
sensing, cellular response as well as chemotherapy, which is a 
very new and significant research on dynamic mechano-biology 
in tumor therapy.
Hence, we construct a TME-responsive nanoenzyme 
(termed as SP-NE) based on reactive oxygen species (ROS)-
responsive dialkynyl-terminated oxalate crosslinked dendritic 
polyglycerol architectures chaperoning both of collagenase 
and a pH-sensitive paclitaxel (PTX) prodrug (Figure  1a). In 
the presence of ROS in TME, the nanoenzymes are disasso-
ciated owing to the cleavage of dialkynyl-terminated oxalate 
crosslinker, causing collagenase release in TME for tumor 
specific relief of the ECM stress and generating PTX prodrug 
for chemotherapy of mechanical stimulated cancer cells. For 
nanostructured drug delivery systems, it is for the first time 
to combine the functions of mechanical remodeling of TME 
and chemotherapeutics in one single and robust system for 
enhanced anti-tumor efficacy, subtly realizing programmed 
mechanical input in TME, cellular mechano-sensing and the 
consequently enhanced chemotherapy. The effect of nano-
enzyme-mediated mechanical alteration on cellular behaviors 
is investigated using human breast cancer MCF-7 cells seeded 
on methacrylated gelatin gels. Remarkably, the enhancement 
of chemotherapeutic efficacy via nanoenzyme-mediated TME 
softening and the corresponding sensitization of cancer cells 
are highlighted. To further support our proof of concept, we 
explore the underlying mechanism and find that nanoenzyme-
modified TME interferes the mechanical signaling transduc-
tion of integrin-focal adhesion kinase (FAK)-Ras homolog 
family member A (RhoA) in enhancing actin cytoskeleton 
dynamics and integrin-FAK-phosphorylated extracellular 
signal regulated kinase (pERK 1/2) in promoting mitosis, 
resulting in improved chemosensitivity and treatment out-
comes (Figure 1b).
2. Results and Discussions
2.1. Design and Characterization of TME-Activatable 
Nanoenzymes
Three main components were prepared to fabricate TME-
activatable nanogels (SP-NG), containing i) dendritic azido 
polyglycerol sulfate (dPGS-N3) with a negative charge for 
enzyme packaging via electrostatic interaction, ii) pH-sensitive 
acetal-linked paclitaxel-dendritic azido polyglycerol macro-
molecular prodrug (dPG(N3)-ace-PTX) which can release PTX 
in its pristine nature under endo/lysosomal pH within tumor 
cells,[33] and iii) the ROS-labile crosslinker dialkynyl-termi-
nated oxalate due to the abundant ROS content in TME.[34] 
dPGS-N3 (10  kDa, 82% sulfation, 10% azidation) was syn-
thesized according to a previous work of our group.[35] pH-
sensitive vinyl ether acrylate-PTX (VEA-PTX) was obtained via 
a “click” type coupling between hydroxyl groups of PTX and 
vinyl ether of VEA, the resultant VEA-PTX was subsequently 
grafted to the dPG(N3)-SH backbone (10  kDa, 8% azidation, 
1% sulfhydrylation), yielding dPG(N3)-ace-PTX (Figure S1a, 
Supporting Information). High-performance liquid chro-
matography (HPLC) assays revealed a PTX content of about 
8.8 wt%. ROS-activatable oxalyl dialkynyl crosslinker was 
obtained via the reaction between oxalyl chloride and pro-
pargyl alcohol (Figure S1b, Supporting Information). The 
terminal alkynyl groups on both ends of the crosslinkers 
were readily linked with azide groups of both dPGS-N3 and 
dPG(N3)-ace-PTX, forming a nanoscale polymer network. 
While the oxalyl ester linker is ROS sensitive and can be 
cleaved at H2O2 concentration of 50 µm.[36,37]
PTX-incorporated nanoenzyme (SP-NE) was generated via 
nanoprecipitation and in situ incorporation of collagenase 
by adding the three components in DMSO into an aqueous 
enzyme solution in phosphate buffer (PB) dropwise. As shown 
in Figure 2a, the size of the nanoarchitectures without enzyme 
(SP-NG) was about 54  nm determined by dynamic light scat-
tering (DLS); the morphology of SP-NG was a spherical shape 
with a diameter of about 50  nm visualized under transmis-
sion electron microscopy (TEM). The colloidal stability of 
SP-NG performed well with little size change against 100-fold 
dilution, as well as in PB containing 10% fetal bovine serum 
(FBS) or whole blood serum for 12 h incubation (Figure S6, 
Supporting Information). The tailorable property of the nano-
carrier (SP-NG) was tested upon exposure to 50 µm H2O2, 
which mimics ROS-abundant condition in TME. DLS results 
revealed a remarkable size decrease from 54 to ≈21 nm at 0.5 h 
(Figure 2b). From TEM graphs, the intact spherical shapes were 
partially dissociated, accompanying with some newly appeared 
small-sized dots at 0.5 h incubation upon H2O2 (Figure  2b). 
After another 22 h incubation, considerable small dots with 
size around several nanometers were observed (Figure 2c). In 
contrast, the size of SP-NG without H2O2 incubation main-
tained almost the same (Figure 2d). The release kinetics of both 
FITC-collagenase and paclitaxel from SP-NE were quantified 
via fluorescence spectrophotometry and HPLC, respectively. 
SP-NE was subjected to PB at pH 7.4 containing 50 µm H2O2 at 
37 °C; the release of FITC-collagenase was rapid with enzyme 
cumulative release of 69% within 24 h incubation, while less 
than 20% FITC-collagenase leakage was observed under a 
physiological condition without H2O2 (Figure  2e), indicating 
ROS-responsive cleavage of the crosslinkers and the subse-
quent efficient enzyme release. In the following, the SP-NE in 
a H2O2-containing media was transferred to acetate buffer with 
endosomal pH (pH 5.0). A considerably enhanced PTX release 
of 65% at 48 h was examined, whereas SP-NE displayed a much 
slower PTX release profile (PTX cumulative release of 18% at 
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48 h) at pH 7.4 (Figure 2e). The programmed disassociation of 
the nanoarchitectures as well as the consequent payload release 
facilitated enzymatic activities in TME and antitumor activities 
in tumor cells.
2.2. SP-NE for ECM Mechanical Remodeling and Sensitization 
in Killing Cells
To investigate the enzymatic activities of dPGS-based nanoen-
zyme without PTX prodrug (termed as S-NE) and SP-NE on 
ECM mechanics, a hydrogel based on methacrylated gelatin 
was adopted as a matrix model for tumor cell culture.[12] The 
hydrogels with different stiffness were formed by dissolving 
methacrylated gelatin at different concentrations ranging from 
5% to 15% and crosslinking upon UV exposure (365  nm, 
10  min) in the presence of catalytic lithium phenyl-2,4,6-
trimethyl-benzoyl-phosphinate. The stiffness of 15% hydro-
gels was determined by rheology with elastic modulus (G′) 
of 5.6  kPa (Figure S9, Supporting Information), which is 
similar to the stiffness in mammary tumor tissues. In the fol-
lowing in vitro studies, human breast tumor MCF-7 cells were 
Figure 1. Schematic illustration about a) components and formation of SP-NE, and b) a proposed mechanism of SP-NE-modulated mechanical remod-
eling of ECM to enhance MCF-7 cells’ susceptibility toward chemotherapy: In the presence of ROS in TME, SP-NE is disassociated, resulting in release 
of collagenase for ECM softening and PTX prodrug for chemotherapy within cells; the dramatically relieved ECM stiffness compromises the mechanical 
signaling events of integrin-FAK-RhoA involved in enhancing F-actin assembly dynamics and integrin-FAK-pERK 1/2 mediating mitosis, leading to an 
unfavorable state of cells with shrinked morphologies and dampened cytoskeleton, and improved chemosensitivity.
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adopted and cultured on methacrylated gelatin gels (5.0  kPa) 
containing 50 µm H2O2, which mimics TME with stiff ECM 
and abundant ROS content. To track the cellular internalization 
profiles of SP-NG in MCF-7 cells seeded on methacrylated gel-
atin gels (5.0  kPa), Cy5-labeled polymer Cy5-dPG(N3)-ace-PTX 
was synthesized and utilized to construct SP-NG (SPCy5-NG). 
The cellular uptake of SPCy5-NG at the presence of 50 µm H2O2 
was quantitatively evaluated in MCF-7 cells via flow cytometry. 
A gradual increase trend of SPCy5-NG internalization in MCF-7 
cells was observed as time prolonged. In detail, Cy5 level in 
SPCy5-NG treated cells at 4 h was 1.5-fold, 3.1-fold, and 22.1-fold 
higher than that at 2 h, 1 h, and 0.5 h respectively (Figure S7, 
Supporting Information). To distinguish whether collagenase 
trapped in nanoenzyme was transported to TME before cel-
lular internalization, FITC-collagenase loaded SPCy5-NG 
(fluorescently labeled nanoenzyme, SPCy5-NEFITC) was employed 
in MCF-7 cells with or without 50 µm H2O2 for CLSM obser-
vation. As displayed in Figure S8, Supporting Informa-
tion, only a few FITC signals while strong Cy5 signals of the 
internalized SPCy5-NEFITC at the presence of 50 µm H2O2 were 
observed in MCF-7 cells at 2 h, which suggested decrosslinking 
of SPCy5-NEFITC and rapid release of FITC-collagenase extracel-
lularly. By contrast, cells treated by SPCy5-NEFITC without H2O2 
for 2 h revealed significantly enhanced FITC signals co-located 
largely with similar Cy5 signals (Figure S8, Supporting Informa-
tion). At 4 h, stronger Cy5 signals but little FITC signals were 
detected in SPCy5-NEFITC plus H2O2 group as compared with 
those at 2 h, while both of stronger Cy5 and FITC signals were 
observed in SPCy5-NEFITC without H2O2 group as compared with 
those at 2 h (Figure S8, Supporting Information). Collectively, in 
the micromilieus containing 50 µm H2O2 which mimics ROS-
abundant TME, FITC-collagenase could be efficiently released 
from nanoenzymes before cellular internalization. Next, we 
assessed the proteolytic activities of nanoenzyme on mechanical 
performances of methacrylated gelatin matrices. As expected, 
the elastic modulus of 15% hydrogel decreased to about 1.5 and 
0.5 kPa after incubation with S-NE in H2O2-containing media for 
5, and 10 h, respectively (Figure S9, Supporting Information). To 
Figure 2. Characterization of SP-NG and SP-NE. a–c) Size change of SP-NG in the media containing 50 µm H2O2 at 0 (a), 0.5 (b), and 22 (c) h deter-
mined by DLS and TEM. d) Size change of SP-NG in PB without H2O2 and PB containing 50 µm H2O2 at different time points measured by DLS 
(n = 3). ***p < 0.001, two-tailed unpaired Student’s t-test. e) Both of enzyme (green curves) and PTX (blue curves) release profiles of SP-NE at different 
conditions: i) incubation in PB at pH 7.4 with or without 50 µm H2O2 for 24 h, mimicking physiological and tumor extracellular ROS-abundant condi-
tions respectively; ii) incubation in PB at pH 7.4 or 5.0 for another 24 h, mimicking physiological and tumor intracellular acidic conditions respectively 
(n = 3). ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis.
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evaluate if the mechanical change of the matrices triggered by 
nanoenzyme could affect a series of cell behaviors including cell 
morphology, spreading, and proliferation, we conducted con-
focal imaging to visualize the cell morphology and spreading. 
After incubation with S-NE (collagenase: 0.1  mg mL−1) at the 
presence of H2O2, MCF-7 human breast tumor cells cultured 
on the stiff gels (5.0  kPa) displayed round morphologies with 
small and impaired actin bundles, which is similar to the group 
treated with SP-NE at the same enzyme concentration and the 
cells cultured on soft gels (0.5 kPa) (Figure 3a). By comparison, 
the untreated cells were well spread with a clear and better-
aligned actin meshwork (Figure  3a). In addition, the quantita-
tive results showed drastically decreased cell spreading areas 
of S-NE-treated MCF-7 cells in a dose-dependent manner, and 
Figure 3. In vitro characterization of SP-NE in MCF-7 cells seeded on methacrylated gelatin gels containing 50 µm H2O2, which mimics TME. a) CLSM 
images depicting actin meshwork change of MCF-7 cells. Cells were treated with different groups for 4 h, and incubated in fresh cell culture media for 
another 48 h. Blue signals, nucleus; green signals, F-actin. Scale bar: 50 µm; scale bar in inserted images: 10 µm. b) Quantification of cell spreading 
areas from CLSM images in (a) (n = 10). *p < 0.05; **p < 0.01; ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis. c) Western blotting results of 
expressions of proteins FAK, RhoA mediating actin assembly, as well as pERK 1/2 involved in cell mitosis in MCF-7 cells receiving the above treatments. 
d) CCK-8 assays of MCF-7 cells treated by different groups (collagenase: 0.05 mg mL−1, PTX: 3 µg mL−1) for 48 h (n = 4). For S-NE plus P-NG group, 
cells were pretreated with S-NE for 4 h and replaced with P-NG for another 48 h incubation. ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis.
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the cell spreading areas of both S-NE and SP-NE groups were 
about 200 µm2 versus 741 µm2 of untreated cells and 908 µm2 of 
empty nanocarrier (S-NG) treated cells (Figure 3b). These data 
suggested S-NE and SP-NE softened the mechanical strength of 
the matrix, and subsequently compromised the cell spreading 
degree and the cytoskeleton network, verifying our hypothesis.
The extrinsic mechanical cues from ECM can be associ-
ated with cellular actomyosin cytoskeleton via focal adhesions, 
which contain vinculin and other mechano-sensing complex. 
The immunofluorescent images showed a decline of vinculin 
levels in MCF-7 cells seeded on stiff gels (5.0  kPa) containing 
50 µm H2O2 treated by SP-NE relative to untreated cells on stiff 
gels (5.0 kPa), which is in agreement with cytoskeleton imaging 
results (Figure S10, Supporting Information). The downstream 
proteins FAK and RhoA also play important roles in sensing 
mechanical signaling transduction and sustaining cytoskeletal 
integrity.[38,39] We then assessed whether the integrin-FAK-
RhoA signaling axis was affected upon S-NE and SP-NE treat-
ment. Western blot analysis was carried out in MCF-7 cells 
seeded on methacrylated gelatin gels containing 50 µm H2O2 
following different treatments. The results revealed that the 
protein levels of FAK and RhoA, which fundamentally manipu-
lates cellular behaviors,[40,41] were severely diminished in cells 
treated with S-NE, SP-NE, and collagenase (Figure 3c). Further-
more, another feedback loop of integrin-FAK-pERK 1/2, which 
is crucial for mitosis and cell proliferation,[42] was also identi-
fied to have been weakened (Figure 3c). Altogether, our finding 
uncovered the molecular mechanism underlying SP-NE (or 
S-NE)-induced cell shrinkage and cytoskeletal dampening. 
Hence, TME primed with SP-NE (or S-NE) may provide cancer 
cells a less favorable environment, eventually improving che-
mosensitivity within cancer cells.
To verify our hypothesis, S-NE pre-treated MCF-7 cells were 
further treated with crosslinked dPG(N3)-ace-PTX nanogels 
(P-NG) and the cell viabilities were tested by cell counting kit-8 
(CCK-8). As shown in Figure 3d, S-NE pre-treated MCF-7 cells 
were demonstrated to be more sensitive to P-NG treatment with 
a 30% diminished cell viability as compared to the cells treated 
by P-NG only. Remarkably, SP-NE composed of 50% S-NE for 
TME mechanical remodeling and 50% P-NG for cellular chem-
otherapy was also employed on MCF-7 cells for CCK-8 assays. 
A significant decline of cell viability was observed for cells 
treated with SP-NE (32% cell viability), which was much lower 
than free PTX (59% cell viability) and SP-NG (66% cell viability) 
groups at a PTX dosage of 3 µg mL−1 (Figure 3d), substantiating 
the sensitization and efficacy of SP-NE in killing cancer cells. 
The potential toxicities of the nanocarriers without PTX or col-
lagenase (S-NG) and the nanoenzyme without PTX (S-NE) were 
also tested and demonstrated to show little effect on MCF-7 
cell proliferation (Figure S11, Supporting Information). Collec-
tively, SP-NE combining the functions of both ECM mechanical 
remodeling and the following chemo-sensitization in killing 
cells, offers a new therapeutic avenue.
2.3. SP-NE for Eliciting In Vivo ECM Mechanical Remodeling
Next, we attempted to utilize the novel SP-NE systems for in 
vivo antitumor therapy. First of all, we performed a time-lapse 
monitoring of DIR-loaded SP-NG (SP-NG/DIR) distribution 
throughout MCF-7 tumor-bearing mice following i.v. injec-
tion. The in vivo fluorescence images showed an evident DIR 
fluorescence in the tumor site at 6 h post injection, the tumor 
fluorescence level increased as time prolonged, indicating 
an efficient tumor-homing property of SP-NG (Figure  4a). 
In addition, ex vivo imaging and the corresponding fluores-
cence quantitative results at 24 h also pointed to a same trend 
that the tumor accumulation of SP-NG/DIR was significantly 
higher relative to that in most organs including heart, spleen, 
lung, and kidney (Figure 4b,c). Quantitation of the PTX dis-
tribution profiles indicated the intratumoral PTX level at 
24 h post i.v. injection of SP-NG reached 5.6% of injected 
dose per gram of tissue (%ID g−1) (Figure S12, Supporting 
Information).
After that, SP-NE system was subjected to MCF-7 tumor-
bearing mice for ECM mechanical remodeling. It is well known 
that collagen is the major ingredient of ECM, and the degra-
dation of collagen in the ECM by the enzymes would lead to 
remission of the ECM tension. Using rheology, we found that 
the elastic modulus of MCF-7 tumors after incubation with 
SP-NE, S-NE, and collagenase decreased to 1181, 884, and 571 Pa 
versus 4300–6900 Pa in tumors before incubation (Figure 4d). 
Furthermore, we measured collagen I levels in MCF-7 tumors 
via immunofluorescence staining after different treatments. 
Treatments of SP-NE, S-NE, and collagenase resulted in mas-
sively declined red fluorescence degrees, which correspond to 
collagen I levels (Figure  4e). ELISA analysis revealed collagen 
I levels in MCF-7 tumors were remarkably decreased by 61.1% 
for SP-NE, 64.0% for S-NE, and 73.6% for collagenase versus 
the control group (Figure  4f). These results indicated that 
SP-NE and S-NE could digest the collagen in ECM and relieve 
the mechanical strength of ECM.
2.4. In Vivo Therapeutic Effects of SP-NE
To validate whether SP-NE elicited ECM softening and the fol-
lowing PTX release can promote antitumor activities in vivo, we 
adopted subcutaneous MCF-7 human breast tumor xenografted 
mice models. The tumor-bearing mice were treated with S-NE, 
free PTX, SP-NG, S-NE plus P-NG (mice were pretreated with 
S-NE for 12 h, and then treated with P-NG), or SP-NE respec-
tively (collagenase dosage: 10 mg kg−1, PTX dosage: 3 mg kg−1, 
n  = 6) and the injections were administrated every 3 days. 
From our analysis on day 19 post treatment initiated, mice 
receiving S-NE showed a slight decline of tumor growth with 
tumor inhibition of about 15.1% (Figure 5a,b). Particularly, both 
of the S-NE plus P-NG and SP-NE showed similar effects and 
produced effective inhibition of tumor growth with suppres-
sion ratios of 84.9% and 87.1% separately on day 19, which were 
far more effective than free PTX (41.1% on day 19) and SP-NG 
(56.7% on day 19) groups (Figure 5a,b). All groups showed little 
effect on mice body weight change (Figure S13, Supporting 
Information) and the liver tissues according to histological 
analysis of the liver on day 19 (Figure S14, Supporting Informa-
tion), indicating a good safety of SP-NE in mice.
On day 19, the tumors of all groups were harvested and sub-
jected to histological analysis. The results further manifested 
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that both S-NE plus P-NG and SP-NE treatments caused severe 
damage to tumor tissues with the highest levels of green fluo-
rescence and the extensive necrotic cells as revealed by TUNEL 
and H&E staining, respectively (Figure 5c and Figure S14, Sup-
porting Information).
2.5. In Vivo Validation of SP-NE for Sensitizing  
in Combating Tumors
Finally, we tried to validate our assumption that the enhanced 
chemotherapeutic efficacy of SP-NE was attributed to the inter-
ference of integrin-FAK-RhoA and integrin-FAK-pERK 1/2 
signaling in vivo. To this end, the tumor blocks of each group 
were collected for immunofluorescence staining. Three key 
players (vinculin, RhoA and pERK 1/2) that mediated cellular 
mechanical signaling and the structure of cytoskeletons were 
specifically labeled for CLSM observation. The signals of vin-
culin, RhoA, and pERK 1/2 were widely distributed in the whole 
tumor with a relatively high intensity in PB saline (PBS) group 
but were barely distributed in the tumors with lower intensities 
in the SP-NE-, S-NE-, and collagenase-treated groups (Figure 5d 
and Figure S15, Supporting Information). Consistently, ELISA 
analysis revealed shrinkages of about 55.4% for vinculin expres-
sion, 55.8% for RhoA expression, and 63.5% for pERK 1/2 
expression in SP-NE-treated group relative to the PBS group 
(Figure 5e,f and Figure S15, Supporting Information). The sig-
nificant regression of vinculin, RhoA and pERK 1/2 expression 
by SP-NE treatment thereby provided a molecular mechanism 
of enhanced in vivo anti-tumor outcome treated by SP-NE.
Figure 4. In vivo characterization of SP-NE. a) In vivo fluorescence images of MCF-7 tumor-bearing mice receiving DIR-loaded SP-NG at different 
time points. b) Ex vivo fluorescence images of the major organs or tissues treated with DIR-loaded SP-NG at 24 h. c) Quantification of fluorescence 
intensity of the organs or tissues according to ex vivo fluorescence images (n = 3). d) Elastic modulus (G′) of MCF-7 tumors before and after different 
treatments at a collagenase concentration of 0.05 mg mL−1 at 37 °C for 10 h measured by rheology at a strain of 0.1% and a frequency of 1 Hz (n = 4). 
***p < 0.001, two-way ANOVA, Bonferroni’s post-hoc analysis. e) CLSM immunofluorescence images of collagen expression in MCF-7 tumors treated 
by different groups. Blue signals, nucleus; red signals, collagen (n = 6). Scale bar: 100 µm. f) ELISA analysis of collagen levels in MCF-7 tumors treated 
by different groups (n = 3). ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis.
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Figure 5. In vivo therapeutic efficacy of SP-NE in MCF-7 tumor-bearing mice models. a) Tumor volume change of different groups (n = 6). Mice were intrave-
nously administrated equivalent collagenase dosage of 10 mg kg−1 and PTX dosage of 3 mg kg−1 on days 1, 4, 7, and 10. b) Relative tumor weight of different 
groups at the end of the experiment (n = 6). **p < 0.01; ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis. c) TUNEL staining of MCF-7 tumors from 
different groups at the end of the experiment. Scale bar: 50 µm. d) CLSM immunofluorescence images of MCF-7 tumors from different groups at the end of 
the experiments. Blue signals, nucleus; red signals, vinculin; green signals, RhoA. Scale bar: 100 µm. e,f) ELISA analysis of vinculin (e) and RhoA (f) levels 
in MCF-7 tumors treated by different groups at the end of the experiments (n = 3). **p < 0.01; ***p < 0.001, one-way ANOVA, Tukey’s post-hoc analysis.
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3. Conclusion
In this work, a ROS-responsive nanogel architecture com-
bining collagenase and a PTX prodrug (SP-NE) was success-
fully developed for ECM mechanical remodeling and enhanced 
chemotherapy sensitized by relieved tumor stress. Collagenase 
was efficiently released from SP-NE due to abundant ROS in 
TME for ECM digestion, resulting in about 10-fold reduction 
in tumor stiffness as well as 4-fold shrinkage in cell spreading 
areas, which in turn greatly aided chemotherapeutics of PTX in 
cancer cells with 30% diminishment of cell viability relative to 
free PTX. A significant tumor inhibition of 87.1% was achieved 
in MCF-7 tumor-bearing mice receiving SP-NE at a low dosage 
of 3  mg equiv. PTX kg−1. Furthermore, the underlying mech-
anism was proposed and verified that the SP-NE treatment 
downregulated cellular mechanical signaling pathways of 
integrin-FAK-RhoA in increasing F-actin assembly dynamics 
and integrin-FAK-pERK 1/2 in promoting mitosis via sof-
tening ECM both in vitro and in vivo. Therefore, our approach 
enriches arsenal of TME modifying strategies for better cancer 
treatment outcomes. Our research extends the understanding 
on mechano-biology of TME and can guide the design of nano-
medicines for cancer therapy.
4. Experimental Section
Materials: 2-Iminothiolane hydrochloride (Traut’s reagent, 98%), 
paclitaxel (PTX, 95%), p-toluenesulfonic acid monohydrate (p-TSA, 
99%), oxalyl chloride (99%), propargyl alcohol (99%), collagenase 
(95%), gelatin, methacrylic anhydride (94%) were bought from Sigma-
Aldrich and used as received. Polymers dendritic azido polyglycerol 
sulfate (dPGS-N3, 10  kDa, 10% azidation, 82% sulfation), dendritic 
azido polyglycerol (dPG-N3, 10 kDa, 10% azidation), gelatin methacrylate 
(degree of substitution: 70%), and VEA, were synthesized according to 
previous reports.[35,43]
Preparation and Characterization of SP-NE: For preparation of SP-NE, 
polymers dPGS-N3 (50 µL, 10  mg mL−1), dPG(N3)-ace-PTX (50 µL, 
10 mg mL−1), and the crosslinker oxalyl dialkynyl (4 µL, 10 mg mL−1) were 
first dissolved in DMSO, and then the mixture was added into 2.5 mL 
PB (pH 7.4, 5 mm) containing collagenase (0.12 mg mL−1) dropwise and 
the whole solution was stirred overnight for a complete crosslinking 
followed by dialysis against PB (pH 7.4, 5  mm) for 8 h to remove 
unentrapped collagenase and DMSO. The size and morphology were 
characterized via DLS and TEM.
Enzyme loading capacity was determined to be 16.8 wt% via BCA 
assays, and fluorescein isothiocyanate-labeled collagenase (FITC-COL) 
was used for in vitro enzyme release studies. Typically, 0.5  mL SP-NE 
solution entrapped with FITC-COL was added in a dialysis tube (Spectra/
Pore, MWCO 1 000 000) followed by immersion in 20 mL PB (pH 7.4) 
at 37  °C either with or without H2O2 (50 µm) for 24 h. Afterward, the 
dialysis media was replaced with PB at pH 7.4 or acetate buffer at pH 
5.0 for another 24 h. At certain time intervals, 6  mL of release media 
was collected and detected via HPLC (Shimadzu LC20AD, Japan) 
and fluorometry (Agilent Technologies, USA). The experiments were 
performed in triplicate.
In Vitro Characterization of SP-NE: To mimic tumor extracellular 
matrix, gelatin methacrylate hydrogel with mechanical strength of 5 kPa 
was fabricated as cell culture matrix. Briefly, 100 µL gelatin methacrylate 
solution (150  mg mL−1) blended with 0.5% (w/v) lithium phenyl-2,4,6-
trimethyl-benzoyl-phosphinate was irradiated under 365 nm for 10 min 
using a UV box. The mechanical features of methacrylated gelatin 
gels were measured via Malvern rheometer kinexus equipped with 
8 mm parallel-plate geometry. Matrix stiffness data was recorded from 
frequency sweeps performed at a strain of 0.1% and a frequency of 1 Hz. 
The enzymatic effects on the stiffness of methacrylated gelatin gels were 
conducted by incubating gels with S-NE in medium containing 50 µm 
H2O2 at a collagenase concentration of 0.05 mg mL−1 at 37  °C for 5 h 
and 10 h respectively. The formed gels were then washed with PB for 
three times, and replaced with cell culture media containing 50 µm H2O2 
for the following in vitro experiments. Herein, human breast tumor 
MCF-7 cells were adopted and cultured in DMEM (high glucose, Gibco) 
supplemented with 10% 10% FBS (Gibco), 100 µg mL−1 penicillin, and 
100 U mL−1 streptomycin (Gibco).
MCF-7 cells were seeded on methacrylated gelatin gels containing 
50 µm H2O2 coating on a coverslip with a diameter of 12  mm at a 
density of 5000 cells cm−2. 12 h later, cells were treated with PBS, 
S-NG, S-NE, and SP-NE for 4 h respectively, followed by replacement 
of fresh cell culture media for another 48 h incubation. To visualize 
cell morphologies, cells from different groups were fixed with 1% 
paraformaldehyde for 30 min and then permeabilized with 0.1% Triton-
100 in PBS for 1 h. Afterwards the cells were stained with 4′-6-diamidino-
2-phenylindole (DAPI, 1:1000, Thermo Fischer Scientific, USA) and Alexa 
Fluor 488 phalloidin (fluorescent phalloidin was used for visualizing 
F-actin, 1:500, Thermo Fischer Scientific, USA) in PBS for 10 min. Finally, 
the cells were imaged by a confocal microscope (SP8, Leica, Germany). 
Cell spreading area was quantified according to F-actin signals and 
analyzed via Image J (n = 10).
In Vivo Antitumor Activity: The therapeutic effects of SP-NE 
mediated ECM degradation in TME and chemotherapy in tumor cells 
were performed in a MCF-7 human breast tumor-bearing mice model 
by injecting MCF-7 cells (5 × 106 cells per mouse) into the right hind 
flank of the female nude mice. The animal experiments were performed 
in accordance with the protocols approved by China Pharmaceutical 
University. When the tumor volume reached 100 mm3, mice were 
randomly divided into 6 groups (n  = 6) and individually administrated 
with PBS, S-NE, PTX, SP-NG, S-NE plus P-NG, and SP-NE intravenously 
(collagenase dosage: 10 mg kg−1, PTX dosage: 3 mg kg−1). For S-NE plus 
P-NG group, mice were treated with S-NE and subsequent P-NG at 12 h 
later. The treatments repeated every 3 days and ended at day 10. Tumor 
volume and body weight of mice in each group were observed and 
recorded. At day 19 post treatment initiated, tumor blocks of mice were 
collected and weighed for tumor inhibition analysis.
In Vivo Mechanical Remodeling of ECM: The mechanical properties 
of the tumor tissues with different treatment were also measured via 
shear rheology. Briefly, the tumor samples were freshly resected from 
subcutaneous human breast MCF-7 tumor-bearing mice, and obtained 
as a cylindrical shape with a size of 8  mm in diameter and 2  mm in 
thickness for rheological measurement. The excised tumor samples 
were then incubated with PBS, P-NG, free PTX, SP-NE, S-NE, and 
free collagenase in medium containing 50 µm H2O2 at a collagenase 
concentration of 0.05 mg mL−1 at 37 °C for 10 h respectively. Afterward 
all the tumor samples were processed for measurement again. Elastic 
modulus (G′) of tumor tissues was determined by the frequency sweeps 
performed at a strain of 0.1% and a frequency of 1  Hz. To further 
elucidate the effect of nanoenzymes on tumor mechanical stiffness in 
vivo, MCF-7 tumor-bearing mice with tumor volume of about 200 mm3 
were injected with PBS, SP-NE, S-NE, and collagenase individually. 2 days 
later, all the tumor tissues were collected, embedded in the paraffin, and 
sliced. After incubation in 5% BSA solution to block nonspecific binding, 
tumor sections were stained with specific antibody of collagen I (1:500, 
Abcam, ab34710, UK), and then incubated with Alexa Fluor 488-labeled 
secondary antibody (1: 1000, Thermo Fischer Scientific, USA). The cell 
nuclei were stained with DAPI, and the tumor samples were visualized 
under CLSM. For the quantitative determination of collagen I level in 
tumors treated by different groups, a commercially available ELISA kit 
for collagen type I (Col I, CUSABIO, P. R. China) was used, the tumor 
tissue homogenates collection and the assay procedure were conducted 
according to the manufacturer’s instructions.
To verify the underlying mechanism of SP-NE modulated mechanical 
signaling pathways of integrin-FAK-RhoA and integrin-FAK-pERK 1/2 in 
vivo, the sectioned slices were also subjected to anti-vinculin (1: 100, 
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Abcam, ab129002, UK), anti-RhoA (1:150, Abcam, ab187027, UK) or 
anti-pERK 1/2 (1:100, Sigma, USA) antibodies, and following Alexa 
Fluor 488 and 647-labeled secondary antibodies (1:400, Invitrogen) 
solution containing DAPI after incubation in 5% BSA solution. Relative 
expressions of vinculin, RhoA and pERK 1/2 were observed under 
CLSM. For the quantitative determination of vinculin, RhoA, and pERK 
1/2 expressions in tumors treated by different groups, commercially 
available ELISA kits for vinculin (VCL, CUSABIO, P. R. China), RhoA 
(FineTest, P. R. China), and pERK1/2 (Abcam, ab176640, UK) were used, 
the tumor tissue homogenates collection and the assay procedure were 
conducted according to the manufacturer’s instructions.
Statistical Analysis: Data were presented as mean ± standard 
deviation. For comparisons, the experimental data was analyzed using 
a two-tailed unpaired Student’s t-test, one-way ANOVA with Tukey’s 
post-hoc test or two-way ANOVA with Bonferroni’s post-hoc test. 
p < 0.05 was considered as statistically significant (*p < 0.05, **p < 0.01, 
***p < 0.001).
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